KFAR MALAL, Israel, February 28, 2017 /PRNewswire/ --
Medial EarlySign (earlysign.com), a developer of machine
Maccabi, one of Israel's leading integrated delivery networks, is feeding its members' electronic medical records (EMRs) into ColonFlag to identify the top 1% at highest risk of undiagnosed CRC. All of the members analyzed by the system were not up to date with their CRC screening. Once flagged, individuals are referred for further evaluation.
"Despite the high survival rates associated with the early detection of colorectal cancer, one third of patients eligible for screening are not being addressed," said Professor Varda Shalev, M.D., M.P.A., Director, Institute for Health Research and Innovation for Maccabi Healthcare. "Medial EarlySign's algorithms, based on machine learning, have enabled us to identify those patients at the highest risk of harboring cancer earlier and prioritize resources accordingly."
Over the first twelve months of the Maccabi implementation, ColonFlag evaluated almost 80,000 individuals, of which 690 were flagged as those at highest risk for CRC. Of the 690 patients identified, 220 colonoscopies were performed and 42% had findings, including 20 cases (10%) of cancer, and further 20 individuals who had either intermediate or high risk adenomas.
"These results with Maccabi illustrate the immense potential of implementing Medial EarlySign's technology to accurately indicate subpopulations at risk of a range of serious health conditions including cancers, metabolic disorders and chronic diseases," said Ori Geva, CEO, Medial EarlySign. "While traditional systems react to visible symptoms, our prediction-based solution enables providers to identify patients at risk of harboring or developing life threatening illnesses, for earlier intervention and treatment. Colorectal cancer is just one of several potential clinical outcomes that our game-changing platform addresses."
ColonFlag is not yet cleared by the FDA for commercial use in the USA.
About Medial EarlySign
Medial EarlySign's advanced algorithm platform accurately detects the likelihood of disease for subpopulations using basic medical information, such as blood test results, and other EMR data. The company's predictive tools provide physicians with actionable insight, while providing insurers with effective models to flag and focus on patients at risk, helping to prioritize resources, save money and improve care. Medial EarlySign's platform addresses numerous potential clinical outcomes, including cancers, diabetes and other life-threatening illnesses. Founded in 2009, the company is headquartered in Kfar Malal, Israel. For more information, please visit http://www.earlysign.com.
Follow Medial EarlySign on LinkedIn: Medial EarlySign and Twitter: @MedialEarlySign
Media Contact Finn Partners for Medial EarlySign Ellie Hanson [email protected] +972-2-589-2006
SOURCE Medial EarlySign
Subscribe to our Free Newsletters!
Erythropoietin is a hormone secreted by kidneys in response to low oxygen levels in tissues ...
Local anesthesia is a type of anesthesia generally used to block pain sensation only in a specific ...
Sea food allergy is the adverse response of the body''s immune system to the proteins present in ...View All